Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINATION: Afatinib and Chemotherapy Followed by Osimertinib and Chemotherapy in EGFR Positive NSCLC
NCT05298176Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: Disease Control Rate at 18 months. Started Jan 2022; status: completed.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05298176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298176.